SpecGx LLC Initiates Class II Recall for Oxycodone and Acetaminophen Tablets Due to Missing Imprints
SpecGx LLC has initiated a Class II nationwide recall for 74,544 bottles of Oxycodone and Acetaminophen CII Tablets (7.5 mg/325 mg) manufactured at its Webster Groves, MO facility. The recall, D-0255-2026, stems from a potential for missing tablet imprints, posing significant risks for patient safety and regulatory compliance. This event underscores critical quality control vulnerabilities for pharmaceutical procurement and supply chain integrity.
What the FDA Found: SpecGx LLC Initiates Class II Recall for Oxycodone and Acetaminophen Tablets
On December 16, 2025, SpecGx LLC, based in Webster Groves, Missouri, initiated a voluntary Class II nationwide recall, identified as D-0255-2026, for 74,544 bottles of its Oxycodone and Acetaminophen CII Tablets USP, 7.5 mg/325 mg. The specific product lot affected is 0522J23493, with an expiration date of March 2027. The primary reason for this recall is a critical manufacturing defect: a potential for the imprint to be missing on tablets. This issue impacts product NDC 0406-0522-01, alongside other listed NDCs including 0406-0512, 0406-0522, and 0406-0523, covering various package configurations. For procurement directors, this event necessitates an immediate review of inventory and supplier qualification processes for opioid analgesics. The Class II classification, indicating that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote, still carries significant risk. Regulatory affairs heads must assess the implications of such a quality control failure, particularly for a Schedule II controlled substance like Oxycodone and Acetaminophen, which demands stringent oversight.
SpecGx LLC's Manufacturing Footprint: Webster Groves Facility and Product Scope
The recalled Oxycodone and Acetaminophen CII Tablets are manufactured by SpecGx LLC at its facility located at 385 Marshall Ave, Webster Groves, MO 63119-1831, within the United States. This facility is responsible for producing the affected human prescription drug, which is distributed nationwide. The product, a combination opioid analgesic, is available in multiple package NDC configurations, including 0406-0512-01, 0406-0512-05, 0406-0512-62, 0406-0512-23, 0406-0512-91, 0406-0522-01, 0406-0522-62, 0406-0522-05, 0406-0522-23, 0406-0523-01, 0406-0523-62, 0406-0523-05, and 0406-0523-23. For supply chain VPs, this highlights the concentration of production for a vital controlled substance at a single site. Any disruption or quality issue at the Webster Groves facility directly impacts the national supply of this specific pain medication. Business development executives should note the broad market presence of these NDCs, indicating a significant footprint for SpecGx LLC in the oral analgesic market, and consider the potential for market shifts or increased scrutiny on competing products.
Implications for Pharmaceutical Procurement and Supply Chain Resilience
The recall of Oxycodone and Acetaminophen tablets due to missing imprints carries substantial commercial and operational implications. For procurement directors, the absence of clear imprints on tablets can lead to critical medication errors, patient confusion, and potential for diversion, especially given the controlled substance status of Oxycodone. This necessitates a re-evaluation of incoming quality control checks and supplier audit protocols. Supply chain VPs must consider the immediate impact of removing 74,544 bottles from nationwide distribution, which could strain inventory levels and affect patient access to this essential pain management medication. While the recall is Class II, the nature of the defect—a fundamental failure in product identification—demands a proactive response to ensure supply chain resilience. This incident underscores the importance of diversifying sourcing strategies for critical drug components and finished products, even when dealing with established manufacturers. Regulatory affairs heads should prepare for heightened scrutiny from the FDA on manufacturing process controls, particularly those related to visual inspection and product serialization, to prevent similar occurrences across their portfolios.
Broader Regulatory Landscape: Contextualizing Recent FDA Actions
This SpecGx LLC recall for missing tablet imprints occurs within a broader context of intensified FDA regulatory vigilance across the pharmaceutical industry. Recent parallel events highlight a consistent focus on manufacturing quality and product integrity. For instance, Essential Wellness Pharma faced a Class II recall for Progesterone Injection due to sterility assurance failures, and Spectra Medical Devices initiated a Class II recall for Lidocaine HCl Injection for similar sterility deficiencies. Guardian Drug Co. Inc. also conducted a nationwide recall for Calcium Carbonate Antacids due to metallic contamination, while Eugia US LLC recalled Lidocaine HCl Injection for labeling deficiencies. These incidents, occurring in the first half of 2026, collectively signal that the FDA is actively enforcing Good Manufacturing Practices (GMP) across various product types and defect categories. For business development executives, this environment suggests that companies with robust quality management systems and transparent manufacturing processes will gain a competitive advantage. Procurement and regulatory affairs teams must recognize that the FDA's scrutiny extends beyond efficacy and safety to fundamental aspects of product quality, including physical attributes like tablet imprints and labeling accuracy. Proactive investment in quality assurance and compliance infrastructure is no longer merely a cost center but a critical enabler of uninterrupted market access and brand reputation.